Physician profile
Derrick Robert Ward
NPI 1366490286
$5,894.74
in general payments reported to CMS, 2019-2025
40 companies · $1,648 in 2025
The $1,648 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $71.91 · 2021: $591 · 2022: $693 · 2023: $1,075 · 2024: $1,635 · 2025: $1,648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,192 · Consulting Fee: $105 · Education: $61.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,191.74 |
| Consulting Fee | $104.59 |
| Education | $61.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,067.68 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $823.48 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Regeneron Healthcare Solutions, INC. | $632.88 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $436.01 | 2020-2025 | Nucala, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $298.65 | 2022-2025 | Takhzyro, Cuvitru, Hyqvia |
| Genentech USA, INC. | $285.67 | 2019-2025 | Xolair |
| Grifols USA, LLC | $274.44 | 2020-2025 | Xembify, Prolastin-C Liquid |
| Amgen INC. | $229.85 | 2022-2025 | Tezspire |
| Csl Behring | $220.62 | 2019-2025 | Hizentra, Haegarda |
| Pharming Healthcare, INC. | $153.44 | 2021-2024 | Ruconest |
| Sanofi-Aventis U.S. LLC | $151.98 | 2022-2023 | |
| Hospira, INC. | $144.73 | 2022-2024 | |
| Kaleo, INC. | $137.59 | 2023-2024 | Auvi-Q |
| Biocryst US Sales Co., LLC | $121.36 | 2022-2025 | Orladeyo |
| Adma Biomanufacturing LLC | $104.59 | 2023-2025 |
Show all 36 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derrick Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.